Peptide Development Checklist: Key Challenges to Address Early

Peptide Development Checklist: Key Challenges to Address Early

Peptides sit between small molecules and larger biologics, and they bring development risks of their own. Sequence-specific behavior, aggregation, fibrillation and chemical degradation can all affect stability and potency. High concentrations, multi-dose presentations and potent molecules add formulation, manufacturing and safety constraints on top of that.

Many of these risks can be predicted. Finding them early saves time, material and rework later in development.

This checklist covers four areas to address from the start: molecular complexity, formulation, manufacturing and occupational safety. For each one, it explains why it matters and what to consider, so your team can ask the right questions before key decisions are made.

Download the checklist below to see where peptide-specific risks typically sit and how to turn them into a robust development strategy.

Developing a Peptide Drug Product? Let’s Talk

Whether you’re assessing a new sequence, trying to stabilize a formulation that keeps degrading, or planning scale-up with a potent molecule, our team can help. We combine in silico assessment, formulation development and analytical characterization to find peptide-specific risks early and turn them into a clear development plan.